₹ 14938
₹646- ₹679
22
₹725
7
1 Aug 2024
Download5 Aug 2024
6 Aug 2024
Application Details
Akums Drugs and Pharmaceuticals Limited IPO opens for subscription on July 30, 2024, and will close on August 1, 2024. The company is set to list on the stock exchanges on August 6, 2024. The shares will have a face value of ₹2 each, with a price band ranging from ₹646 to ₹679 per share. Investors can apply for shares in lots of 22, with the minimum investment amounting to ₹14,938 for a single lot, while the maximum investment for retail investors will be ₹194,194 for 13 lots (286 shares).
The total issue size of the IPO is 27,345,162 shares, aggregating up to ₹1,856.74 crore. This comprises a fresh issue of 10,014,727 shares, raising ₹680 crore, and an offer for sale (OFS) of 17,330,435 shares, aggregating up to ₹1,176.74 crore. Employees of Akums Drugs and Pharmaceuticals will benefit from a discount of ₹64 per share.
The IPO has a structured reservation for different categories of investors. Qualified Institutional Buyers (QIBs) will be offered not more than 75% of the net offer, while Retail Individual Investors (RIIs) will have access to not less than 10% of the offer. Non-Institutional Investors (NIIs) or High Net-worth Individuals (HNIs) will be allotted not less than 15% of the offer.
Key dates for the IPO process include the basis of allotment on August 2, 2024, initiation of refunds on August 5, 2024, and credit of shares to demat accounts also on August 5, 2024. The cut-off time for UPI mandate confirmation is set for 5 PM on August 1, 2024.
About Akums Drugs and Pharmaceuticals Limited
Company Overview
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a leading pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
Services and Capabilities
The company provides comprehensive end-to-end solutions for product development, manufacturing, research and development (R&D) of formulations, and preparation and submission of regulatory dossiers in both Indian and global markets. It also offers various testing services. Additionally, Akums manufactures and sells branded drugs and active pharmaceutical ingredients (APIs).
As a CDMO, Akums manufactures a diverse range of dosage forms, including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections, and gummy bears. The company holds intellectual property rights for the manufacturing processes of several of its formulations. Its primary focus is on delivering end-to-end product development and manufacturing solutions to its clients, along with formulation research, regulatory dossier preparation and filing, and other testing services.
Achievements and Production Capacity
Akums has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of India’s top 30 pharmaceutical companies by revenue. For its CDMO business, Akums operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually as of September 30, 2023.
The company plans to expand its production capacity with two additional production units to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies, such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP), and the United States National Sanitation Foundation (US NSF).
FAQ
IPO stands for "Initial Public Offering." It's the process through which a privately-held company becomes publicly traded by offering its shares to the general public and listing them on a stock exchange for trading. This allows the company to raise capital from investors and grants individuals and institutions the opportunity to invest in and own a portion of the company.
The life cycle of an IPO, or Initial Public Offering, begins with a company's decision to go public. It involves hiring underwriters, registering with regulatory authorities, determining the IPO price, marketing to investors, and the subscription period where investors place orders for shares. After allocation and listing, shares become publicly tradable, and the company enters the secondary market. Ongoing reporting and corporate governance are crucial as the company continues to operate as a publicly-traded entity. The IPO aims to raise capital for growth and provides investors with opportunities to trade shares in the company.
An IPO (Initial Public Offering) is when a private company goes public by selling shares to the public. Investors buy these shares, giving them ownership in the company. It's a way for companies to raise capital and expand. The process involves underwriters, regulatory filings, setting the IPO price, and marketing to investors. After the IPO, shares can be traded on a stock exchange. IPOs offer opportunities and risks, so investors should research and consider carefully.
"Upcoming IPOs" refers to initial public offerings that have been announced by private companies but have not yet occurred. These are companies that plan to go public in the near future by issuing shares to the public and listing them on a stock exchange. Investors often keep an eye on upcoming IPOs as they represent opportunities to invest in companies at their early stages of public trading, potentially capturing growth potential. These offerings are typically accompanied by significant media and investor attention as they approach their launch dates.